Heghine Khachatryan: Willebrand Disease – Similar Bleeding Phenotype, Distinct Pathophysiology
Heghine Khachatryan, Editor-in-Chief of Hemostasis Today, Head of Hemophilia and Thrombosis Center at Yeolyan Hematology and Oncology Center, shared Glanzmann’s Research Foundation’s post on LinkedIn, adding:
“Willebrand Disease: Similar Bleeding Phenotype, Distinct Pathophysiology
Glanzmann thrombasthenia (GT) and Type 2 von Willebrand disease (VWD) may present with remarkably similar mucocutaneous bleeding symptoms—including
recurrent epistaxis, gingival bleeding, easy bruising, and heavy menstrual bleeding—making the differential diagnosis clinically challenging.
However, these disorders arise from fundamentally different defects in primary hemostasis.
Glanzmann thrombasthenia is an inherited platelet function disorder caused by qualitative or quantitative defects of the platelet integrin αIIbβ3 (GPIIb/IIIa), resulting in
severely impaired platelet aggregation despite a normal platelet count.
In contrast, Type 2 von Willebrand disease is characterized by qualitative abnormalities of von Willebrand factor that disrupt platelet adhesion and/or factor VIII stabilization, depending on the subtype.
Because clinical manifestations frequently overlap, diagnosis should never rely solely on bleeding symptoms.
Comprehensive laboratory evaluation—including platelet aggregation studies, flow cytometric assessment of platelet glycoproteins, von Willebrand factor antigen and activity assays,
multimer analysis, and targeted molecular testing when indicated—is essential for establishing the correct diagnosis and guiding appropriate therapy.
Accurate distinction between these rare bleeding disorders is critical, as therapeutic strategies differ substantially.
Misclassification may lead to ineffective treatment, avoidable bleeding complications, or unnecessary transfusion exposure.
Precision diagnosis remains the cornerstone of personalized hemostatic care.”
Glanzmann’s Research Foundation shared a post on LinkedIn about a recent article by Navin Raj Ramamurthy et al. published in Cureus, adding:
“Glanzmann Thrombasthenia and Type 2 Von Willebrand Disease often share similar symptoms, including nosebleeds, gum bleeding, and heavy menstrual bleeding,
making an accurate diagnosis difficult without specialized testing.
A recent case report highlights the critical role of platelet function studies and von Willebrand testing in distinguishing these disorders and ensuring patients receive the most appropriate treatment.”
Title: Platelet Function Disorders: Glanzmann Thrombasthenia and Type 2 Von Willebrand Disease
Authors: Navin Raj Ramamurthy, Shashank M., Sugil E., Selvakumar Selvaraj, Namitha Narayanan, Ashokraj Selvam, Dhivyapriya S.
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 22, 2026, 04:15Wolfgang Miesbach: First AAV Gene Therapy Data in Adolescents With Haemophilia B
-
Sep 22, 2026, 04:03Emmanuel J Favaloro: 100 Years of VWD – A Special Virtual Issue
-
Sep 22, 2026, 03:31Mostafa Elshazly: How Is Humidification Used During Non Invasive Ventilation?
-
Sep 22, 2026, 03:05Sumyea Kabir: Jehovah’s Witnesses Update Their Position on Blood Components
-
Sep 22, 2026, 02:33Gerardo Moscatelli: The Spike Protein Cascade – From Endothelial Binding to Vascular Collapse
-
Sep 21, 2026, 20:56George Touma: ApoB Should Be Central to All Lipid Guidlines
-
Sep 21, 2026, 20:55Christopher Robinson: Obstetric Risks Are Seen at the Extremes of Birthweight
-
Sep 21, 2026, 20:54Emicizumab for Refractory GI Bleeding in Myeloma-Associated Acquired VWD – JTH
-
Sep 21, 2026, 20:52Ross Baker: ASH 2026 Guidelines on Iron Deficiency in HMB and Bleeding Disorders